Recently, Suzhou Ruibo Biotechnology Co., Ltd. (stock code: 06938. HK), a leading enterprise in small nucleic acid drugs, officially listed on the main board of the Hong Kong Stock Exchange, marking a breakthrough in the capitalization of Chinese pharmaceutical companies in the siRNA innovation drug field and injecting new momentum into the industry's development.
In this global announcement, Ruibo Biotechnology issued a total of 31.6104 million shares at a price of HKD 57.97 per share, raising a total of over HKD 1.8 billion in funds. The public announcement of this IPO has received over 100 times the subscription amount, and the international announcement has reached 16.7 times the subscription amount, reflecting the high recognition of global investors for the value and strength of the company. The proceeds raised from this IPO will provide solid financial support for the advancement of the company's core business. At the same time, the issuance introduced 12 heavyweight cornerstone investors including Huaxia Fund, Dacheng International and Dacheng Fund, Taikang Life Insurance, etc., demonstrating the firm confidence of top institutions in the company's long-term prospects. The fundraising will focus on four major directions: promoting global multi center clinical research of core products; Support the research and development of pipeline in preclinical and clinical stages; Iterative upgrade of small nucleic acid delivery technology and other platforms; Supplement working capital and general enterprise purposes.
GLP-1
1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablet
(3)Capsule
(4)Injection
(5)Liquid Drops
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
GLP-1 CAS 87805-34-3
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Manufacturer: BLOOM TECH Xi'an Factory
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4
1 billion yuan! Zhongsheng Ruichuang GLP-1/GIP agonist authorized by Qilu Pharmaceutical
On January 16, 2026, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (hereinafter referred to as "Zhongsheng Xichuang"), a holding subsidiary of Guangdong Zhongsheng Pharmaceutical Co., Ltd., held a strategic cooperation signing ceremony with Qilu Pharmaceutical Co., Ltd. (hereinafter referred to as "Qilu Pharmaceutical") to jointly announce the signing of a license agreement on the innovative drug GLP-1/GIP double cake point receptor super long-acting agonist RAY1225 injection. Zhongsheng Ruichuang authorized Qilu Pharmaceutical to produce and commercialize RAY1225 injection in China (including Chinese Mainland, Hong Kong, Macao and Taiwan), and Zhongsheng Ruichuang reserved all rights, ownership and interests of the licensed intellectual property rights.
RAY1225 injection is an innovative structural peptide drug developed by Zhongsheng Ruichuang with global independent intellectual property rights. It has dual agonist activity of GLP-1 receptor and GIP receptor, and thanks to its excellent pharmacokinetic properties, it has the potential for ultra long acting drug injection once every two weeks. At present, the safety and effectiveness of RAY1225 injection in the Phase II clinical trial (REBUILDING-2 study) for the treatment of obese/overweight patients in China, the safety and effectiveness of RAY1225 injection in combination with oral hypoglycemic drugs in the treatment of patients with type 2 diabetes,
Custom Notebook Solutions
the Phase I clinical trial (SHINING-3) controlled by Smeaglutide injection, the safety and effectiveness of RAY1225 injection alone in the treatment of patients with type 2 semiuria, and the placebo controlled Phase I clinical trial (SHINING-2) have successfully completed the enrollment of all participants. Zhongsheng Ruichuang will continue to uphold a rigorous attitude and promote the Phase II clinical trial of RAY1225 injection in a high-quality, efficient, and scientifically standardized manner.
Yuanda Pharmaceutical's innovative RDC drug has been applied for listing in China
On January 19, 2026, Yuanda Pharmaceutical (0512. HK) submitted a new drug application (NDA) for the diagnosis of prostate cancer to the National Medical Products Administration (NMPA) for the development of an innovative radionuclide conjugate drug (RDC TLX591 CDx (Muccix8,9allium Ga 68 PSMA-11).
In addition, the RDC product TLX591 used by Yuanda Pharmaceutical for the treatment of prostate cancer has been approved to join the international multicenter phase II clinical trial in China. In the future, the combination of the two products is poised to bring more accurate and efficient diagnosis and treatment plans for Chinese prostate cancer patients.
This NDA application includes data from the TLX591 CDx clinical study in China, which published positive preliminary results in December 2025. The study is a single arm, open label phase clinical trial that used TLX591 CDx in over 100 patients with biochemical recurrence of prostate cancer and performed positron emission tomography/computed tomography (PET/CT) or positron emission tomography/magnetic resonance imaging (PET/MRD) testing to evaluate the diagnostic efficacy of the product, as well as its safety and tolerability in the Chinese population. According to the clinical top line results, the overall positive predictive value (PPV) of TLX591 CDx for detecting tumors reached 94.8% (confidence interval, C: 85.9% -98.2%), confirming that the clinical experience of using TLX591 CDx for diagnosis in Chinese patients is comparable to the research results of non Chinese patients. Even in patients with extremely low prostate-specific antigen (PSA) values and in different metastatic sites, their PPV remains at a high level.
East China Medicine's "Three Target" FIC Drug DR10624 Completed MASLD/MASH Phase I Clinical Enrollment
On January 19, 2026, Zhejiang Daoer Biotechnology Co., Ltd., a subsidiary of East China Pharmaceutical Co., Ltd. ("Daoer Biotechnology"), a clinical stage biopharmaceutical company that develops innovative biological therapy drugs for metabolic diseases and cancer, announced today that its independently developed long-acting tri specific agonist DR10624, which targets fibroblast growth factor 21 receptor (FGF21R), glucagon receptor (GCGR), and glucagon like peptide-1 receptor (GLP-1R), has been successfully used for the treatment of metabolic related fatty acids. All patients were enrolled in the Phase II clinical study "DR10624-202 Study" for liver disease (MASLD)/metabolism related steatohepatitis (MASH). DR10624 is a drug developed by Dole Biotech that can simultaneously target GLP-1 receptor (GLP-1R) and GCG The world's first long-acting triple target agonist of receptor (GCGR) and FGFR1/KIothop (FGF21R), fused with engineered IgG1FC from the N-terminal GLP-1R/GCGR targeting chimeric peptide segment, and fused with recombinant FGF21 mutant at the C-terminal of Fc. Preclinical animal studies have shown that DR10624 has significant therapeutic effects in reducing cholesterol, weight, and blood sugar.